ARHGEF10L Promotes Cervical Tumorigenesis via RhoA-Mediated Signaling

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• ARHGEF10L is a guanine nucleotide exchange factor regulating Rho GTPase activity and implicated in tumorigenesis.
• Previous studies linked ARHGEF10L to increased cervical carcinoma risk.
• This study elucidates the specific role and mechanism of ARHGEF10L in cervical tumors.

Purpose of the Study:

• To investigate the pathogenic role of ARHGEF10L in cervical cancer.
• To elucidate the molecular mechanisms by which ARHGEF10L influences cervical tumor progression.

Main Methods:

• HeLa cervical carcinoma cells were transfected with ARHGEF10L-overexpressing plasmids or siRNA.
• Cell proliferation, migration, and apoptosis were assessed using CCK-8, wound-healing, and apoptosis assays.
• Rho pull-down assays and RNA-sequencing were employed to identify the underlying molecular pathways.

Main Results:

• ARHGEF10L overexpression enhanced cell proliferation, migration, and epithelial-to-mesenchymal transition (EMT), while reducing apoptosis.
• ARHGEF10L upregulated GTP-RhoA, ROCK1, and phospho-ERM, indicating activation of the RhoA-ROCK1-ERM signaling pathway.
• RNA-sequencing revealed significant alterations in gene expression, including increased HSPA6, and identified dysregulated pathways such as Toll-like receptor signaling.

Conclusions:

• ARHGEF10L acts as an oncogene in cervical cancer by promoting proliferation, migration, and EMT through the RhoA-ROCK1-ERM pathway.
• ARHGEF10L may be a novel therapeutic target for cervical carcinoma and other cancers.
• The study highlights ARHGEF10L's role in regulating key cellular processes involved in tumorigenesis.